Lineage Cell Therapeutics, Inc.
LCTX· NYSE
LCTXLineage Cell Therapeutics, Inc.
Filed Mar 17, 2014 · 10-K · 76 days after period end · 0001140361-14-013083
| Metric | Q4 2013 | Q4 2012 | Q4 2011 | Q4 2010dderived from reported figures |
|---|---|---|---|---|
| Revenue | $1.67M | $1.07M | $1.63M | — |
| Net Income | -$19.61M | -$6.04M | -$5.14M | — |
| EPS Diluted | -$0.35 | -$0.12 | -$0.10 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
ended Dec 31, 2013 · filed Mar 17, 2014 · 76 d after period end
